Plus Therapeutics (NASDAQ:PSTV) Given New $3.00 Price Target at Maxim Group

Plus Therapeutics (NASDAQ:PSTV) had its target price lowered by Maxim Group from $4.00 to $3.00 in a research report released on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently commented on the stock. Ascendiant Capital Markets increased their price objective on shares of Plus Therapeutics from $20.00 to $20.50 and gave the company a “buy” rating in a research note on Thursday, June 5th. Wall Street Zen upgraded shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reduced their price objective on shares of Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 27th. D. Boral Capital restated a “hold” rating and issued a $9.00 price target on shares of Plus Therapeutics in a research report on Wednesday, June 25th. Finally, D Boral Capital downgraded shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.88.

Plus Therapeutics Price Performance

NASDAQ PSTV opened at $0.54 on Monday. Plus Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.31. The company has a market capitalization of $32.43 million, a price-to-earnings ratio of -0.24 and a beta of 0.67. The company’s fifty day moving average price is $0.43 and its two-hundred day moving average price is $0.68.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. The company had revenue of $1.39 million for the quarter, compared to the consensus estimate of $1.08 million. As a group, analysts anticipate that Plus Therapeutics will post -2.3 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Plus Therapeutics stock. Jane Street Group LLC purchased a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 117,454 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned about 0.19% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.